Moderna Overview
| Company: | Moderna |
|---|---|
| CEO: | Mr. Stephane Bancel |
| Symbol: | MRNA |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| About |
Moderna, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccineslude COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics; Metagenomi; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics and changed its name to Moderna in August 2018. Moderna was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
-
Address:
200 Technology Square
-
City | State | Zip | Country:
Cambridge | MA | 02139 | US
-
Phone:
617 714 6500
- Website:
Revenue
Net Income
Employees
Revenue by Segment
Revenue by Region
Income Statement
Operating Income
Research & Development
Tax Rate (%)
Assets & Liabilities | Cash Flow
Total Assets
Total Liabilities
Capital Expenditure
Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Debt to Equity
Profitability
Gross Profit Margin (%)
Operating Income Margin (%)
Net Income Margin (%)
Earning Per Share
EBITDA
Free Cash Flow (FCF)
Valuation
Enterprise value
Enterprise value to Revenue
Enterprise value to EBITDA
Competitors’ Revenue
